Table III.
HR HPV genotype distribution.
| Genotype distribution | HPV DNA+ (n = 87) | HR HPV DNA+ (n = 71) | Oncogenic infection (n = 47) | Passenger infection (n = 24) |
|---|---|---|---|---|
| HPV 16+ (n = 55) | 63.2% | 77.4% | 85.1% (40) | 62.5% (15) |
| Before 2010 (n = 19) | 51.3% (19/37) | 61.2% (19/31) | 73.3% (11/15) | 50% (8/16) |
| After 2010 (n = 36) | 72% (36/50) | 90% (36/40) | 90.6% (29/32) | 87.5% (7/8) |
| p | Ns | 0.008 | Ns | Ns |
| HR non-16 infections (n = 26) | 29.8% | 36.6% | 23.4% (11) | 62.5% (15) |
| Before 2010 (n = 18) | 48.6% (18/37) | 58% (18/31) | 36.3% (4/15) | 87.5% (14/16) |
| After 2010 (n = 8) | 16% (8/50) | 20% (8/40) | 21.8% (7/32) | 12.5% (1/8) |
| p | 0.002 | 0.002 | ns | < 0.001 |
| HR coinfections (n = 16) | 18.3% | 22.5% | 19.1% (9) | 29.1% (7) |
| Before 2010 (n = 10) | 27% (10/37) | 32.2% (10/31) | 20% (3/15) | 66.6% (7/16) |
| After 2010 (n = 6) | 12% (6/50) | 15% (6/40) | 18.7% (6/32) | 0 (0/8) |
| p | Ns | Ns | Ns | 0.05 |
Ns: not significant.